Computational design and evaluation of mRNA- and protein-based conjugate vaccines for influenza A and SARS-CoV-2 viruses.
Amir ElaloufTomer KedaryaHadas ElaloufAriel RosenfeldPublished in: Journal, genetic engineering & biotechnology (2023)
The in silico-designed vaccine against IAV and SARS-CoV-2 showed good population coverage and immune response with predicted T- and B-cell epitopes, favorable molecular docking, Ramachandran plot results, and good protein expression. It fulfilled safety criteria, indicating potential for preclinical studies and experimental clinical trials.
Keyphrases
- molecular docking
- sars cov
- immune response
- clinical trial
- respiratory syndrome coronavirus
- molecular dynamics simulations
- binding protein
- dendritic cells
- cancer therapy
- toll like receptor
- cell therapy
- protein protein
- healthcare
- human health
- affordable care act
- open label
- inflammatory response
- small molecule
- climate change
- study protocol
- phase iii
- bone marrow
- double blind
- health insurance